Literature DB >> 9922304

Neutrophils, Helicobacter pylori, and nonsteroidal anti-inflammatory drug ulcers.

A S Taha1, S Dahill, C Morran, N Hudson, C J Hawkey, F D Lee, R D Sturrock, R I Russell.   

Abstract

BACKGROUND & AIMS: Gastric injury by nonsteroidal anti-inflammatory drugs (NSAIDs) is minimal in neutropenic animals. This study examined peptic ulcer development in the presence or absence of gastric neutrophils in patients requiring long-term use of NSAIDs.
METHODS: Gastric histology, neutrophils, and Helicobacter pylori were assessed in 120 patients randomized to receive placebo or 20 or 40 mg famotidine twice daily as prophylaxis against NSAID-related ulcers and who underwent endoscopy at 0, 4, 12, and 24 weeks.
RESULTS: In 43 patients without gastric neutrophils, ulcers developed in 1 of 14 (7.7%) taking placebo, 2 of 16 (12.5%) taking 20 mg famotidine, and none of 13 taking 40 mg famotidine. However, in 77 patients with neutrophils, ulcers developed in 13 of 28 (47. 4%) taking placebo (P < 0.001), 3 of 26 (12.6%) taking 20 mg famotidine, and 3 of 23 (13%) taking 40 mg famotidine. Eight of 46 patients (17%) without H. pylori had neutrophils compared with 69 of 74 (93%) with both H. pylori and neutrophils (P < 0.001).
CONCLUSIONS: Gastric neutrophils increase the incidence of ulceration in long-term NSAID users. Because neutrophils exist with H. pylori, eradicating this infection might prevent NSAID-related peptic ulcers.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9922304     DOI: 10.1016/s0016-5085(99)70120-4

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  10 in total

1.  Aspirin injury and H pylori.

Authors:  A Schmassmann
Journal:  Gut       Date:  2002-05       Impact factor: 23.059

Review 2.  Non-steroidal anti-inflammatory drugs and gastrointestinal damage-problems and solutions.

Authors:  R I Russell
Journal:  Postgrad Med J       Date:  2001-02       Impact factor: 2.401

3.  Influence of Helicobacter pylori infection on healing and relapse of acetic acid ulcers in Mongolian gerbils.

Authors:  Yoshihiro Keto; Misako Ebata; Kazuyoshi Tomita; Susumu Okabe
Journal:  Dig Dis Sci       Date:  2002-04       Impact factor: 3.199

Review 4.  NSAID-induced peptic ulcers and Helicobacter pylori infection: implications for patient management.

Authors:  Francis K L Chan
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

5.  Comparison of CXC chemokines ENA-78 and interleukin-8 expression in Helicobacter pylori-associated gastritis.

Authors:  G Rieder; W Einsiedl; R A Hatz; M Stolte; G A Enders; A Walz
Journal:  Infect Immun       Date:  2001-01       Impact factor: 3.441

Review 6.  Cyclooxygenase 2-implications on maintenance of gastric mucosal integrity and ulcer healing: controversial issues and perspectives.

Authors:  F Halter; A S Tarnawski; A Schmassmann; B M Peskar
Journal:  Gut       Date:  2001-09       Impact factor: 23.059

7.  Helicobacter pylori infection potentiates aspirin induced gastric mucosal injury in Mongolian gerbils.

Authors:  N Yoshida; N Sugimoto; F Hirayama; Y Nakamura; H Ichikawa; Y Naito; T Yoshikawa
Journal:  Gut       Date:  2002-05       Impact factor: 23.059

8.  Biphasic effects of H. pylori infection on low-dose aspirin-induced gastropathy depending on the gastric acid secretion level.

Authors:  Katsunori Iijima; Nobuyuki Ara; Yasuhiko Abe; Tomoyuki Koike; Toshimitsu Iwabuchi; Hirohiko Shinkai; Kaname Uno; Hiroyuki Endo; Naoki Asano; Tooru Shimosegawa
Journal:  J Gastroenterol       Date:  2012-05-02       Impact factor: 7.527

9.  NSAID gastric ulceration: predictive value of gastric pH, mucosal density of polymorphonuclear leukocytes, or levels of IL-8 or nitrite.

Authors:  Akiko Shiotani; Yoshio Yamaoka; Hala M T El-Zimaity; M Ali Saeed; Waqar A Qureshi; David Y Graham
Journal:  Dig Dis Sci       Date:  2002-01       Impact factor: 3.199

10.  Efficacy and safety of Ibuprofen arginine in the treatment of primary dysmenorrhoea.

Authors:  Camil Castelo-Branco; Gemma Casals; Javier Haya; María Jesús Cancelo; José Manasanch
Journal:  Clin Drug Investig       Date:  2004       Impact factor: 2.859

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.